Clinical Trials Logo
  1. Home
  2. Hypercholesterolemia, Familial
  3. NCT04313270

Subclinical Atherosclerosis in Patients With Familial Hypercholesterolemia Treated With Evolocumab®

Hypercholesterolemia, Familial Clinical Trial

Official title:
Subclinical Atherosclerosis in Patients With Familial Hypercholesterolemia Treated With Evolocumab®

Clinical Trial Summary

Protein convertase subtilisin kexin type 9 (PCSK-9) inhibitors demonstrated efficacy in cholesterol reduction and in the prevention of cardiovascular events. The investigators will evaluate changes in lipid profile, oxidation markers and subclinical atherosclerosis in patients with familial hypercholesterolemia (FH) during 12 weeks of treatment with a PCSK-9 inhibitor, Evolocumab®.

Clinical Trial Description

Several studies emphasize the role of high levels of low-density lipoprotein cholesterol (LDL-C) as the main causative factor in atherosclerosis development. Among patients with hypercholesterolemia, those with very high levels of LDL-C exhibit increased prevalence of subclinical atherosclerosis and a higher atherosclerosis progression, thus leading to a significantly higher CV risk. Endothelial dysfunction is the earliest stage of the atherosclerotic process and even a trigger of CV events. Flow-mediated dilation (FMD) is widely accepted as an accurate and non-invasive method to assess vascular reactivity and, in turn, as a surrogate marker of subclinical atherosclerosis and an independent predictor of CV events. It's well known that hypercholesterolemia has been associated with decreased endothelial function and increased oxidative stress. Although statin treatment represented for years the gold standard as lipid lowering therapy, the target LDL-C is not always achieved, mainly among patients with very high levels of LDL-C. More recently, PCSK-9 inhibitors demonstrated efficacy in LDL-C reduction, in the prevention from CV events and in atherosclerotic burden regression. Some data showed an effect of PCSK-9 inhibitors on endothelial function, but no evidence is available on effect on LDL subfractions. Small dense LDL (sd-LDL) are considered an emerging risk factor for cardiovascular disease due to a greater atherogenic potential [ ] and are important markers for predicting CV risk. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04313270
Study type Observational
Source Federico II University
Contact
Status Recruiting
Phase
Start date December 1, 2017
Completion date December 1, 2025
View Details
See also
  Status Clinical Trial Phase
Terminated NCT00384293 - Carotid IMT (Intima Media Thickening) Study (0524A-041)(TERMINATED) Phase 3
Completed NCT04722068 - Regeneron 1331 Kinetics Sub-Study HoFH N/A
Completed NCT04118348 - Evaluating the Efficacy of Pediatric Lipid Screening Alerts N/A
Completed NCT00000594 - NHLBI Type II Coronary Intervention Study Phase 3
Completed NCT04526457 - Is Family Screening Improved by Genetic Testing of Familial Hypercholesterolemia N/A
Completed NCT01753232 - Safety and Efficacy of the DALI LDL-adsorber and MONET Lipoprotein Filter N/A
Completed NCT03018678 - Screening Protocol for a Gene Therapy Trial in Subjects With Homozygous Familial Hypercholesterolemia
Completed NCT00134511 - Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Patients With Genetic High Cholesterol Disorder Phase 3
Completed NCT00134485 - Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia Phase 3
Recruiting NCT04073797 - PET Imaging of Inflammation and Lipid Lowering Study N/A
Terminated NCT01583647 - A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158) Phase 1
Completed NCT00515307 - Bone Marrow Stem Cells as a Source of Allogenic Hepatocyte Transplantation in Homozygous Familial Hypercholesterolemia Phase 1
Recruiting NCT04656028 - Genetic Testing and Motivational Counseling for FH N/A
Terminated NCT00092833 - Investigational Drug in Patients With Hypercholesterolemia or in Patients With Sitosterolemia (0653-026)(COMPLETED) Phase 3
Active, not recruiting NCT04837638 - Diet Quality and Coronary Artery Calcification in Adults With Heterozygous Familial Hypercholesterolemia
Completed NCT00280995 - Dose-escalating Safety Study of ISIS 301012 in Homozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy Phase 2
Completed NCT06231459 - Expression of Pro- and Anti-inflammatory Cytokines During Anti-PCSK9 in Familial Hypercholesterolemia Phase 4
Completed NCT01524289 - Study to Assess the Tolerability and Efficacy of Anacetrapib (MK-0859) Co-Administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020) Phase 3
Completed NCT00281008 - Study of ISIS 301012 (Mipomersen) in Heterozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy Phase 2
Recruiting NCT03989167 - Clinical Decision Support for Familial Hypercholesterolemia N/A